SNGX
- Soligenix, Inc.
()
Overview
Company Summary
Soligenix, Inc. (SNGX) is a biopharmaceutical company that develops and commercializes innovative therapeutics to treat serious inflammatory diseases and rare diseases. The company focuses on developing treatments for areas of high unmet medical need where there are limited or no available treatment options.
Soligenix has two primary areas of focus in its product pipeline: therapeutics for gastrointestinal (GI) disorders and treatments for rare diseases.
In the GI disorders segment, Soligenix is working on developing SGX942, a novel innate defense regulator (IDR), as a treatment for oral mucositis, a common and painful side effect of cancer treatments such as radiation and chemotherapy. SGX942 works by boosting the body's immune response, reducing oral mucositis symptoms, and potentially speeding up the healing process. Soligenix has completed phase 3 clinical trials for SGX942 and is awaiting regulatory approval.
The rare diseases segment includes Soligenix's investigative drugs, such as SGX301 and SGX942, for the treatment of cutaneous T-cell lymphoma (CTCL) and pediatric Crohn's disease, respectively. SGX301 is a novel topical synthetic hypericin that selectively targets CTCL cells and has shown promising results in phase 2 trials. Soligenix has received Orphan Drug Designation from the regulatory authorities for SGX301, which provides certain incentives and benefits for drug development targeting rare diseases.
In addition to its therapeutic pipeline, Soligenix also has a biodefense division, which focuses on developing medical countermeasures for various bioterrorism agents. This division has developed RiVax, a vaccine candidate for ricin toxin exposure, and SGX943, a treatment for gastrointestinal acute radiation syndrome (GI-ARS). These products are intended for potential use in emergency situations, such as bioterrorism attacks or nuclear accidents.
Overall, Soligenix, Inc. aims to address unmet medical needs in the areas of GI disorders, rare diseases, and biodefense, by developing innovative and potentially life-saving treatments.